The putative PAX8/PPARγ fusion oncoprotein exhibits partial tumor suppressor activity through Up-regulation of Micro-RNA-122 and dominant-negative PPARγ activity

Genes and Cancer

Volumn 2, Issue 1, 2011, Pages 46-55

  Reddi, Honey V ^a   Madde, Pranathi ^a   Milosevic, Dragana ^a   Hackbarth, Jennifer S ^a   Algeciras Schimnich, Alicia ^a   Mciver, Bryan ^a   Grebe, Stefan K G ^a   Eberhardt, Norman L ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

Follicular thyroid carcinoma; Fusion protein; Mir 122; Pax8 ppar ; Tumor suppressor

Indexed keywords

CD31 ANTIGEN; HYBRID PROTEIN; MICRORNA; MICRORNA 122; MUTANT PROTEIN; ONCOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRANSCRIPTION FACTOR PAX8; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; FUSION GENE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; MICROVASCULATURE; MICROVESSEL DENSITY; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STABLE EXPRESSION; THYROID ADENOMA; THYROID FOLLICULAR CARCINOMA; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; UPREGULATION;

EID: 79960043127     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601911405045     Document Type: Article

References (35)

1. Farahati J, Geling M, Mader U, et al. Changing trends of incidence and prognosis of thyroid carcinoma in lower Franconia, Germany, from 1981-1995. Thyroid. 2004;14:141-7.
2. Eberhardt NL, Grebe SK, McIver B, Reddi HV. The role of the PAX8/ PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer. Mol Cell Endocrinol. 2010;321:50-6.
3. Nambiar M, Kari V, Raghavan SC. Chromosomal translocations in cancer. Biochim Biophys Acta. 2008;1786:139-52.
4. Gregory Powell J, Wang X, Allard BL, et al. The PAX8/PPARgamma fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARgamma inhibition. Oncogene. 2004;23:3634-41.
5. Au AY, McBride C, Wilhelm KG, Jr., et al. PAX8-peroxisome proliferator- activated receptor gamma (PPARgamma) disrupts normal PAX8 or PPARgamma transcriptional function and stimulates follicular thyroid cell growth. Endocrinology. 2006;147:367-76.
6. Diallo-Krou E, Yu J, Colby LA, et al. Paired box gene 8-peroxisome proliferator-activated receptor-gamma fusion protein and loss of phosphatase and tensin homolog synergistically cause thyroid hyperplasia in transgenic mice. Endocrinology. 2009;150:5181-90.
7. Sahin M, Allard BL, Yates M, et al. PPARgamma staining as a surrogate for PAX8/PPARgamma fusion oncogene expression in follicular neoplasms: clinicopathological correlation and histopathological diagnostic value. J Clin Endocrinol Metab. 2005;90:463-8.
8. Marques AR, Espadinha C, Catarino AL, et al. Expression of PAX8- PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab. 2002;87:3947-52.
9. Cheung L, Messina M, Gill A, et al. Detection of the PAX8-PPAR gamma fusion oncogene in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab. 2003;88:354-7.
10. Dwight T, Thoppe SR, Foukakis T, et al. Involvement of the PAX8/ peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors. J Clin Endocrinol Metab. 2003;88:4440-5.
11. Marques AR, Espadinha C, Frias MJ, et al. Underexpression of peroxisome proliferator-activated receptor (PPAR)gamma in PAX8/ PPARgamma-negative thyroid tumours. Br J Cancer. 2004;91:732-8.
12. Banito A, Pinto AE, Espadinha C, Marques AR, Leite V. Aneuploidy and RAS mutations are mutually exclusive events in the development of well-differentiated thyroid follicular tumours. Clin Endocrinol. 2007;67:706-11.
13. Nakabashi CC, Guimaraes GS, Michaluart P, Jr., Ward LS, Cerutti JM, Maciel RM. The expression of PAX8-PPARgamma rearrangements is not specific to follicular thyroid carcinoma. Clin Endocrinol (Oxf). 2004;61:280-2.
14. Nikiforova MN, Lynch RA, Biddinger PW, et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab. 2003;88:2318-26.
15. French CA, Alexander EK, Cibas ES, et al. Genetic and biological subgroups of low-stage follicular thyroid cancer. Am J Pathol. 2003;162:1053-60.
16. Lacroix L, Mian C, Barrier T, et al. PAX8 and peroxisome proliferatoractivated receptor gamma 1 gene expression status in benign and malignant thyroid tissues. Eur J Endocrinol. 2004;151:367-74.
17. Bai S, Nasser MW, Wang B, et al. MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem. 2009;284:32015-27.
18. Tsai WC, Hsu PW, Lai TC, et al. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology. 2009;49:1571-82.
19. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nature Rev. 2009;10:704-14.
20. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435:834-8.
21. Nikiforova MN, Tseng GC, Steward D, Diorio D, Nikiforov YE. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab. 2008;93: 600-8.
22. Pallante P, Visone R, Croce CM, Fusco A. Deregulation of microRNA expression in follicular cell-derived human thyroid carcinomas. Endocr Relat Cancer. 2010;17:F91-104.
23. Weber F, Teresi RE, Broelsch CE, Frilling A, Eng C. A limited set of human MicroRNA is deregulated in follicular thyroid carcinoma. J Clin Endocrinol Metab. 2006;91:3584-91.
24. Reddi HV, Madde P, Marlow LA, et al. Expression of the PAX8/ PPARgamma fusion protein is associated with decreased neovascularization in vivo: impact on tumorigenesis and disease prognosis. Genes Cancer. 2010;1:480-92.
25. Kroll TG, Sarraf P, Pecciarini L, et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma. Science. 2000;289:1357-60.
26. Lui WO, Zeng L, Rehrmann V, et al. CREB3L2-PPARgamma fusion mutation identifies a thyroid signaling pathway regulated by intramembrane proteolysis. Cancer Res. 2008;68:7156-64.
27. Yin Y, Yuan H, Zeng X, Kopelovich L, Glazer RI. Inhibition of peroxisome proliferator-activated receptor gamma increases estrogen receptor-dependent tumor specification. Cancer Res. 2009;69:687-94.
28. Chang J, Guo JT, Jiang D, Guo H, Taylor JM, Block TM. Liverspecific microRNA miR-122 enhances the replication of hepatitis C virus in nonhepatic cells. J Virol. 2008;82:8215-23.
29. Fajas L, Debril MB, Auwerx J. Peroxisome proliferator-activated receptor-gamma: from adipogenesis to carcinogenesis. J Mol Endocrinol. 2001;27:1-9.
30. Kato Y, Ying H, Zhao L, et al. PPARgamma insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factorkappaB signaling pathway. Oncogene. 2006;25:2736-47.
31. Ying H, Suzuki H, Zhao L, Willingham MC, Meltzer P, Cheng SY. Mutant thyroid hormone receptor beta represses the expression and transcriptional activity of peroxisome proliferator-activated receptor gamma during thyroid carcinogenesis. Cancer Res. 2003;63:5274-80.
32. Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival: modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Meth. 1986;89:271-7.
33. Monahan P, Rybak S, Raetzman LT. The Notch target gene Hes1 regulates cell cycle inhibitor expression in the developing pituitary. Endocrinology. 2009;150:4386-94.
34. Nikiforova MN, Biddinger PW, Caudill CM, Kroll TG, Nikiforov YE. PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol. 2002;26:1016-23.
35. Castro P, Rebocho AP, Soares RJ, et al. PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2006;91: 213-20.